Submitted for Publication: April 4, 2012; final revision received June 21, 2012; accepted July 4, 2012.
Published Online: January 9, 2013. doi:10.1001/2013.jamapsychiatry.24
Author Contributions: Dr Croarkin had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Conflict of Interest Disclosures: Dr Croarkin has received research grant support from Stanley Medical Research Institute, NARSAD (now Brain and Behavior Research Foundation), and Pfizer Inc and has served as a site subinvestigator or principal investigator (without additional compensation) for Eli Lilly and Co, Forest Laboratories Inc, Merck and Co Inc, and Pfizer Inc. Dr Husain has received research grant support from the National Institutes of Health, NARSAD, Stanley Medical Research Institute, Cyberonics Inc, Neuronetics Inc, Advanced Neuromodulation Systems Inc (now part of St Jude Medical Inc), Brainsway Ltd, and NeoSync Inc and has received a grant-in-kind for equipment from Magstim Co Ltd. Dr Emslie has received research and grant support from the National Institutes of Health, BioBehavioral Diagnostics Co, Eli Lilly and Co, Forest Laboratories Inc, GlaxoSmithKline PLC, Shire PLC, and Somerset Pharmaceuticals Inc; has served as a consultant for BioBehavioral Diagnostics Co, Bristol-Myers Squibb Co, Eli Lilly and Co, INC Research LLC, Lundbeck, Pfizer Inc, Seaside Therapeutics Inc, Shire PLC, Valeant Pharmaceuticals International Inc, Validus Pharmaceuticals LLC, and Wyeth Pharmaceuticals Inc (now part of Pfizer Inc); and has served on speakers' bureaus for McNeil Consumer Healthcare (now part of Ortho-McNeil-Janssen Pharmaceuticals Inc, a subsidiary of Johnson and Johnson Services Inc) and Forest Laboratories Inc. Dr Kozel has received research and salary support from a US Department of Defense grant and prior grant support from the National Institute of Mental Health and the National Center for Research Resources; has received a grant-in-kind from Neuronetics Inc for supplies and the use of equipment; and has received research grants from the Defense Academy for Credibility Assessment (formerly the Department of Defense Polygraph Institute; now the National Center for Credibility Assessment), Cephos Corp, and Stanley Medical Research Institute. Dr Daskalakis has received external funding from Neuronetics Inc, Brainsway Ltd, and Aspect Medical Systems Inc; has received travel allowances from Pfizer Inc and Merck and Co, Inc; has received speaker honoraria through Sepracor Inc (now Sunovion Pharmaceuticals Inc); and has served on the advisory board of F. Hoffmann–La Roche Ltd.
Funding/Support: This work was supported by the Ontario Mental Health Foundation, the Canadian Institutes of Health Research, the Grant Family through the Centre for Addiction and Mental Health Foundation, and NARSAD (now Brain and Behavior Research Foundation).
Role of the Sponsors: The sponsors had no role in the study design and conduct; collection, management, analysis, and interpretation of data; or preparation, review, or approval of the manuscript.
Online-Only Material: Listen to an author interview about this article, and others, at http://bit.ly/L4AZtw.
Additional Contributions: Anosha Zanjani, BSc, assisted in preparing the figures and Joshua M. Baruth, PhD, and Taryn Mayes, MS, provided review and thoughtful feedback.